Similar articles for PMID: 17910634

Year	Number of Results
2001	3
2002	1
2003	2
2004	5
2005	6
2006	7
2007	16
2008	14
2009	16
2010	10
2011	9
2012	8
2013	7
2014	4
2021	1
2024	0

1

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease.

Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Muñoz S, Zhao M, Mundy GR. Oyajobi BO, et al. Br J Haematol. 2007 Nov;139(3):434-8. doi: 10.1111/j.1365-2141.2007.06829.x. Br J Haematol. 2007. PMID: 17910634 Free PMC article.

2

Bone building with bortezomib.

Roodman GD. Roodman GD. J Clin Invest. 2008 Feb;118(2):462-4. doi: 10.1172/JCI34734. J Clin Invest. 2008. PMID: 18219395 Free PMC article.

3

The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.

Eda H, Aoki K, Kato S, Okawa Y, Takada K, Tanaka T, Marumo K, Ohkawa K. Eda H, et al. Eur J Haematol. 2010 Jul;85(1):68-75. doi: 10.1111/j.1600-0609.2010.01435.x. Epub 2010 Feb 23. Eur J Haematol. 2010. PMID: 20192985

4

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.

Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A, Rizzoli V. Giuliani N, et al. Blood. 2007 Jul 1;110(1):334-8. doi: 10.1182/blood-2006-11-059188. Epub 2007 Mar 19. Blood. 2007. PMID: 17371942 Free article.

5

Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling.

Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B, Shaughnessy JD Jr. Qiang YW, et al. Blood. 2009 Apr 30;113(18):4319-30. doi: 10.1182/blood-2008-08-174300. Epub 2009 Feb 4. Blood. 2009. PMID: 19196662 Free PMC article.

6

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN. Hurchla MA, et al. Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5. Leukemia. 2013. PMID: 22763387 Free PMC article.

7

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.

Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. Pennisi A, et al. Am J Hematol. 2009 Jan;84(1):6-14. doi: 10.1002/ajh.21310. Am J Hematol. 2009. PMID: 18980173 Free PMC article.

8

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.

Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O. Kaiser MF, et al. Eur J Haematol. 2013 Apr;90(4):263-72. doi: 10.1111/ejh.12069. Epub 2013 Feb 15. Eur J Haematol. 2013. PMID: 23311753

9

Impact of bortezomib on bone health in myeloma: a review of current evidence.

Zangari M, Terpos E, Zhan F, Tricot G. Zangari M, et al. Cancer Treat Rev. 2012 Dec;38(8):968-80. doi: 10.1016/j.ctrv.2011.12.007. Epub 2012 Jan 9. Cancer Treat Rev. 2012. PMID: 22226939 Review.

10

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.

Edwards CM, Lwin ST, Fowler JA, Oyajobi BO, Zhuang J, Bates AL, Mundy GR. Edwards CM, et al. Am J Hematol. 2009 May;84(5):268-72. doi: 10.1002/ajh.21374. Am J Hematol. 2009. PMID: 19296472 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

98 results

Results by year